Oxford Brain Diagnostics

Oxford Brain Diagnostics is a private, commercial-stage diagnostics company leveraging its FDA-cleared and breakthrough-designated MRI biomarker platform to quantify cortical microstructure changes associated with neurodegeneration. Its core technology, CDM®, provides novel endpoints for clinical trials and tools for clinicians, positioning it as a partner for biopharma and a contributor to precision neurology. The company is actively engaged in partnerships and research grants, indicating a transition from technology validation to commercial application in a high-need market.

Cortical Disarray Measurement (CDM®) - an advanced MRI analysis platform that quantifies microstructural disorganization in the brain's cortical minicolumns using diffusion MRI to detect neuroinflammation and neuronal loss.

OBD competes with other advanced MRI analytics firms, PET imaging biomarkers (amyloid, tau), and emerging fluid biomarkers (blood-based p-tau). Its differentiation lies in the direct measurement of cortical microstructure, offering a potential earlier and more sensitive readout of neuronal health and inflammation.